Tumor-specific MHC class II upregulation associated with response to anti-PD-L1 therapy in patients with urothelial cancer. Updated interim analysis of a phase I/Ib study of enfortumab vedotin plus ...
NSD2 inhibition as a therapeutic approach for treatment-induced neuroendocrine prostate cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results